A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm
About this trial
This is an interventional treatment trial for Myelofibrosis focused on measuring Phase 1, Phase 2, Oncology, BET Inhibitor, Ruxolitinib, Pelabresib
Eligibility Criteria
Inclusion Criteria:
Phase 2 part: Patients with confirmed diagnosis of MF who meet all of the following criteria:
- ANC ≥ 1 x 10^9/L without the assistance of granulocyte growth factors
- Peripheral blood blast count <10%
- ECOG performance status ≤ 2.
- Adequate hematological, renal, hepatic, and coagulation laboratory assessments
- No prior treatment with a BET inhibitor
- Patients must give written informed consent to participate in this study before the performance of any study-related procedure.
For Arm 1 and 2 the following criteria should be considered:
- Patients with confirmed diagnosis of MF who meet all of the following criteria
- Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher
- Spleen volume ≥ 450 cm^3 by MRI or CT for Cohorts 1B and 2B OR RBC transfusion dependent (defined as an average of ≥2 units of RBC transfusions per month over the 12 weeks prior to enrollment for Cohorts 1A and 2A)
- At least 2 symptoms measurable (Score ≥ 1) using the Myelofibrosis Symptom Assessment Form Version 4.0 (MFSAF v4.0)
- Platelet count ≥ 75 x 10^9/L without the assistance of thrombopoietic factors or transfusions for at least 14 days
Monotherapy Arm (Arm 1): Previously treated with a JAK inhibitor and be intolerant, resistant, refractory, or lost response to the JAK inhibitor; have not received the JAK inhibitor within 2 weeks prior to the start of study drug, or are ineligible to be treated with a JAK inhibitor
Combination Arm (Arm 2): Must have received single agent ruxolitinib and be on a stable dose for a minimum 8 weeks but have disease that is not being adequately controlled by ruxolitinib
For Arm 3 (JAK inhibitors naïve) the following criteria should be considered:
- Patients with confirmed diagnosis of MF who meet all of the following criteria
- Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher
- Platelet count ≥ 100 x 10^9/L without the assistance of thrombopoietic factors or transfusions
- Spleen volume ≥ 450 cm^3 by MRI/CT
- At least 2 symptoms measurable (Score ≥ 3) or a total score of ≥ 10 using the MFSAF v4.0
- No prior treatment with JAKi allowed
For Arm 4 (ET Expansion) the following criteria should be considered:
- Patients with a confirmed diagnosis of ET
- High-risk disease, defined as meeting at least one of the following criteria:
- Age > 60 years
- Platelet count > 1500 × 10^9/L (at any point during the patient's disease)
- Previously documented thrombosis, erythromelalgia, or migraine
- Previous hemorrhage related to ET
- Diabetes or hypertension requiring pharmacological therapy for > 6 months
Have ≥2 symptoms with an average score ≥ 3 over the 7-day period prior to Cycle 1 Day 1 or an average total score of ≥15 over the 7-day period prior to Cycle 1 Day 1 using the using the MPN SAF
- Platelets > 600 × 10^9/L
- Resistant or intolerant to HU
Exclusion Criteria:
- Current known active or chronic infection with human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C.
- Impaired cardiac function or clinically significant cardiac diseases
- Patients with Child-Pugh Class B or C
- Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of CPI-0610 and/or ruxolitinib, including any unresolved nausea, vomiting, or diarrhea that is CTCAE Grade >1
- Prior treatment with a BET inhibitor.
- Pregnant or lactating women
- Any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study
- Patients unwilling or unable to comply with this study protocol.
Sites / Locations
- Mayo Clinic Arizona
- UCLA Medical Center
- Mayo Clinic Jacksonville
- Northwestern University - Lurie Comprehensive Cancer Center
- Massachusetts General Hospital Cancer Center
- University of Michigan Medical Center
- Washington University School of Medicne Neuromuscular Division Department of Neurology Research
- Memorial Sloan Kettering Cancer Center
- ICAHN School of Medicine at Mount Sinai
- Weill Medical College and New York Presbyterian Hospital
- The University of Texas MD Anderson Cancer Center
- Froedtert & Medical College of Wisconsin
- UZ Leuven - Campus Gasthuisberg
- AZ Sint-Jan Burgge-Oostende AV- Campus Sint-Jan
- ZNA Stuyvenberg Antwerpen
- University of Alberta Hospital
- St. Paul's Hospital
- Juravinski Cancer Centre
- Princess Margaret Cancer Centre
- Jewish General Hospital
- Institut de cancérologie du Gard - Hematologie clinique
- CHRU de Lille - Hopital Claude Huriez
- Institut Gustave Roussy
- CHRU de Lille - Hopital Claude Huriez - Maladies du Sang
- CHU - Hopital Saint Louis - Centre D'Investigations Clinique
- Universitätsklinikum Bonn
- Universitätsklinikum Leipzig AöR
- Institue of Hematology "L. and A. Seràgnoli"
- Servizio Sanitario Regionale Emilia-Romagna - Azienda Unita Sanitaria Locale (AUSL) di Rimini - Ospedale Infermi di Rimini
- AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can
- Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda
- IRCCS Policlinico San Matteo, Università degli studi di Pavi
- Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fon
- Azienda Ospedaliero-Universitaria Careggi
- AOU Maggiore della Carità
- Maastricht University Medical Center
- VUmcResearch B.V.
- Erasmus Universitair Medisch Centrum Rotterdam
- Instytut Hematologii i Transfuzjologii w Warszawie
- Uniwersyteckie Centrum Kliniczne
- Oxford University Hospitals
- Belfast City Hospital
- University of Cambridge
- University Hospital of Wales
- Beatson West of Scotland Cancer Centre
- University College London Hospital's NHS foundation Trust
- Guys and St Thomas' Hospital - Haematology
- The Christie Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm (MF patients treated with pelabresib alone)
Arm 2: Prior JAKi Combination Arm
Arm 3: JAKi Naïve Combination Arm
Arm 4: Essential Thrombocythemia (ET) Monotherapy Arm
Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi (pelabresib alone) Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)
Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib (pelabresib + Ruxolitinib) Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)
Open to patients with MF who have not previously received a JAKi (pelabresib + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher
Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)